At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Psilocybin-facilitated Treatment for Cocaine Use
In Brief
A Phase 2 clinical trial evaluating Psilocybin and Diphenhydramine for Cocaine-Related Disorders. Completed, enrolled 40 participants across 1 site.
Detailed Summary
The primary purpose of this study is to evaluate the feasibility and estimate the efficacy of psilocybin-facilitated treatment for cocaine use. We also will monitor the impact of psilocybin-facilitated treatment on the use of other drugs and outcomes relevant to cocaine involvement. MRI assessment is a unique aspect of this study. As a potential biological mechanism of psilocybin's effect includes changes in default mode network functional connectivity (Carhart-Harris et al., 2012), we will determine if psilocybin's therapeutic effects are mediated by such changes. Moreover, as Glx (a brain metabolite that reflects glutamate) abnormalities have been shown to play a role in cocaine addiction, we will determine if psilocybin impacts Glx in the anterior cingulate cortex and hippocampus.
Study Details
Timeline
Interventions
this has been used in treating obsessive-compulsive disorders, cluster headaches, anxiety, and drug dependence.
This drug will be used as the control. Diphenhydramine is a histamine blocker.